MA32684B1 - Dérivés de picolinamide en tant qu'inhibiteurs de kinase - Google Patents

Dérivés de picolinamide en tant qu'inhibiteurs de kinase

Info

Publication number
MA32684B1
MA32684B1 MA33733A MA33733A MA32684B1 MA 32684 B1 MA32684 B1 MA 32684B1 MA 33733 A MA33733 A MA 33733A MA 33733 A MA33733 A MA 33733A MA 32684 B1 MA32684 B1 MA 32684B1
Authority
MA
Morocco
Prior art keywords
kinase
compositions
compounds
kinase inhibitors
inhibiting
Prior art date
Application number
MA33733A
Other languages
Arabic (ar)
English (en)
Inventor
Matthew T Burger
Wooseok Han
Jiong Lan
Gisele Nishiguchi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32684(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32684B1 publication Critical patent/MA32684B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux composés de picolinamide, des compositions et des procédés d'inhibition de l'activité kinase d'intégration de provirus de Maloney (kinase PIM) associée à la cancérogenèse chez un sujet humain ou animal. Dans certains modes de réalisation, les composés et compositions sont efficaces pour inhiber l'activité d'au moins une kinase PIM. Les nouveaux composés et compositions peuvent être utilisés seuls ou en combinaison avec au moins un agent additionnel pour le traitement d'un trouble véhiculé par une sérine/thréonine kinase ou un récepteur tyrosine kinase, tel que le cancer.
MA33733A 2008-09-02 2011-04-01 Dérivés de picolinamide en tant qu'inhibiteurs de kinase MA32684B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9366608P 2008-09-02 2008-09-02
US22566009P 2009-07-15 2009-07-15
PCT/EP2009/061205 WO2010026124A1 (fr) 2008-09-02 2009-08-31 Dérivés de picolinamide en tant qu’inhibiteurs de kinase

Publications (1)

Publication Number Publication Date
MA32684B1 true MA32684B1 (fr) 2011-10-02

Family

ID=41228825

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33733A MA32684B1 (fr) 2008-09-02 2011-04-01 Dérivés de picolinamide en tant qu'inhibiteurs de kinase

Country Status (38)

Country Link
US (4) US8329732B2 (fr)
EP (1) EP2344474B1 (fr)
JP (2) JP5412519B2 (fr)
KR (1) KR101345920B1 (fr)
CN (3) CN102203079B (fr)
AU (1) AU2009289319C1 (fr)
BR (1) BRPI0918268B1 (fr)
CA (1) CA2734415C (fr)
CL (1) CL2011000454A1 (fr)
CO (1) CO6351725A2 (fr)
CR (1) CR20110114A (fr)
DK (1) DK2344474T3 (fr)
DO (1) DOP2011000067A (fr)
EA (1) EA020136B1 (fr)
EC (1) ECSP11010859A (fr)
ES (1) ES2551900T3 (fr)
GE (1) GEP20135849B (fr)
HN (1) HN2011000629A (fr)
HR (1) HRP20151410T1 (fr)
HU (1) HUE026381T2 (fr)
IL (1) IL211291A (fr)
MA (1) MA32684B1 (fr)
ME (1) ME01291A (fr)
MX (1) MX2011002365A (fr)
MY (1) MY150136A (fr)
NI (1) NI201100052A (fr)
NZ (1) NZ591449A (fr)
PE (1) PE20110298A1 (fr)
PL (1) PL2344474T3 (fr)
PT (1) PT2344474E (fr)
RS (1) RS54506B1 (fr)
SI (1) SI2344474T1 (fr)
SM (1) SMT201600005B (fr)
SV (1) SV2011003849A (fr)
TW (1) TWI434843B (fr)
UY (1) UY32085A (fr)
WO (1) WO2010026124A1 (fr)
ZA (1) ZA201101118B (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2455382B1 (fr) 2005-12-13 2016-10-26 Incyte Holdings Corporation Pyrrolo[2,3-b]pyridines et pyrrolo[2,3-b]pyrimidines à substitution hétéroaryle en tant qu'inhibiteurs de la janus kinase
US20140249135A1 (en) * 2007-03-01 2014-09-04 Novartis Ag Pim kinase inhibitors and methods of their use
EP3070090B1 (fr) 2007-06-13 2018-12-12 Incyte Holdings Corporation Utilisation des sels de l'inhibiteur de janus kinase (r)-3-(4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl) -3-cyclopentylpropanenitrile
WO2010026121A1 (fr) * 2008-09-02 2010-03-11 Novartis Ag Inhibiteurs bicycliques des kinases
MX2011002365A (es) 2008-09-02 2011-04-04 Novartis Ag Derivados de picolinamida como inhibidres de cinasa.
JP5775070B2 (ja) 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
SG176111A1 (en) 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
JP6161537B2 (ja) * 2010-04-07 2017-07-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物及び使用の方法
RS54824B1 (sr) 2010-05-21 2016-10-31 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
JP2013530199A (ja) * 2010-07-06 2013-07-25 ノバルティス アーゲー キナーゼ阻害剤として有用な環状エーテル化合物
CA2818542A1 (fr) 2010-11-19 2012-05-24 Incyte Corporation Derives pyrrolopyridine et pyrrolopyrimidine a substitution cyclobutyle utilises comme inhibiteurs des jak
WO2012068440A1 (fr) 2010-11-19 2012-05-24 Incyte Corporation Pyrrolopyridines et pyrrolopyrimidines à substitution hétérocyclique utilisées en tant qu'inhibiteurs des jak
EP2675816A4 (fr) * 2011-02-14 2014-08-13 Univ Alberta Catalyseurs à base d'acide boronique et procédés d'utilisation associés pour l'activation et la transformation d'acides carboxyliques
WO2012120415A1 (fr) * 2011-03-04 2012-09-13 Novartis Ag Composés de cyclohexyle tétrasubstitués à titre d'inhibiteurs de kinases
UY33930A (es) * 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
JP2014516941A (ja) 2011-04-29 2014-07-17 アムジェン インコーポレイテッド Ｐｉｍ阻害剤としての二環式ピリダジン化合物
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
EP2734205B1 (fr) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Inhibiteurs de protéine kinase hétérocycliques
US9458151B2 (en) * 2011-08-11 2016-10-04 Jikai Biosciences, Inc. Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
US9453003B2 (en) * 2011-08-11 2016-09-27 Jikai Biosciences, Inc. Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
US9173883B2 (en) 2012-05-21 2015-11-03 Novartis Ag Ring-substituted N-pyridinyl amides as kinase inhibitors
WO2014033631A1 (fr) 2012-08-31 2014-03-06 Novartis Ag N- (3-pyridyl)-biarylamides en tant qu'inhibiteurs de kinase
WO2014033630A1 (fr) 2012-08-31 2014-03-06 Novartis Ag Nouveaux carboxamides d'aminothiazole en tant qu'inhibiteurs de kinase
DK2900657T3 (da) 2012-09-26 2020-05-04 Hoffmann La Roche Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
CN103724301A (zh) * 2012-10-10 2014-04-16 上海特化医药科技有限公司 (2r)-2-脱氧-2,2-二取代-1,4-核糖内酯及其制备方法和用途
CN113384546A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
JP6437452B2 (ja) * 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
WO2014138168A1 (fr) 2013-03-06 2014-09-12 Incyte Corporation Procédés et intermédiaires pour la génération d'un inhibiteur de jak
US9113629B2 (en) * 2013-03-15 2015-08-25 Dow Agrosciences Llc 4-amino-6-(4-substituted-phenyl)-picolinates and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylates and their use as herbicides
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
JP2016527305A (ja) * 2013-08-08 2016-09-08 ノバルティス アーゲー Ｐｉｍキナーゼ阻害剤の組合せ
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
AU2014354821A1 (en) 2013-11-27 2016-05-26 Novartis Ag Combination therapy comprising an inhibitor of JAK, CDK and PIM
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (fr) 2014-01-31 2019-03-27 Novartis AG Molécules d'anticorps anti-tim-3 et leurs utilisations
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
JP6554480B2 (ja) 2014-03-18 2019-07-31 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト オキセパン−２−イル−ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物と使用方法
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2016010897A1 (fr) 2014-07-14 2016-01-21 Incyte Corporation Composés carboxamide hétéroaromatiques bicycliques utiles en tant qu'inhibiteurs de kinases pim
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
JO3589B1 (ar) * 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
WO2016196244A1 (fr) 2015-05-29 2016-12-08 Incyte Corporation Composés de pyridineamine utiles en tant qu'inhibiteurs de kinase pim
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP3878465A1 (fr) 2015-07-29 2021-09-15 Novartis AG Polythérapies comprenant des molécules d'anticorps tim-3
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
CN105254624B (zh) * 2015-09-18 2019-08-09 上海吉铠医药科技有限公司 异噻唑衍生物pim激酶抑制剂及其制备方法与在制药中的应用
CN105130959B (zh) * 2015-09-18 2018-08-03 上海吉铠医药科技有限公司 嘧啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3370768B9 (fr) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Anticorps se liant spécifiquement à pd-1 et leurs utilisations
WO2017106656A1 (fr) 2015-12-17 2017-06-22 Novartis Ag Molécules d'anticorps anti-pd-1 et leurs utilisations
CN107519175A (zh) * 2016-06-21 2017-12-29 上海方予健康医药科技有限公司 一种嘧啶化合物或其盐在制备用于预防和/或治疗与flt3相关的疾病或障碍的药物中的应用
CN107522696B (zh) * 2016-06-21 2019-02-19 上海方予健康医药科技有限公司 一种嘧啶类化合物的盐酸盐及其制备方法和用途
CN107522695B (zh) * 2016-06-21 2018-09-14 上海方予健康医药科技有限公司 一种pim激酶抑制剂的盐酸盐及其制备方法和用途
WO2018009466A1 (fr) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018237173A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
EP3645008A4 (fr) * 2017-06-30 2020-12-09 Bristol-Myers Squibb Company Composés quinolinycyclohexylpropanamide substitués et procédés améliorés pour leur préparation
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EA202091830A1 (ru) 2018-01-30 2020-12-29 Инсайт Корпорейшн Способы и промежуточные соединения для получения ингибитора jak
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
MD3773593T2 (ro) 2018-03-30 2024-10-31 Incyte Corp Tratament hidradenitei supurative utilizând inhibitori ai JAK
CN117838695A (zh) 2018-04-13 2024-04-09 住友制药肿瘤公司 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
MX2020013085A (es) 2018-06-05 2021-03-02 Crinetics Pharmaceuticals Inc Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos.
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
CN110078706B (zh) * 2019-05-31 2022-02-01 浙江师范大学 一种伊马替尼衍生物及其制备方法和用途
CN110452164B (zh) * 2019-09-10 2022-07-22 上海皓鸿生物医药科技有限公司 Pim447关键中间体的制备方法
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US12479825B2 (en) 2019-11-07 2025-11-25 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
EP4077307B1 (fr) 2019-12-18 2025-03-12 Crinetics Pharmaceuticals, Inc. Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations
WO2021133563A1 (fr) 2019-12-23 2021-07-01 Crinetics Pharmaceuticals, Inc. Antagonistes du récepteur du sous-type 2 de la mélanocortine à base de pipéridine spirocyclique (mc2r) et leurs utilisations
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112915086B (zh) * 2021-01-27 2022-04-12 广州市力鑫药业有限公司 一种含有Akt靶向激酶抑制剂的药物组合物
JP2024510260A (ja) 2021-03-19 2024-03-06 クリネティックス ファーマシューティカルズ，インク． 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト
WO2023003014A1 (fr) * 2021-07-21 2023-01-26 中外製薬株式会社 Procédé de production d'un dérivé arylamide
EP4611753A1 (fr) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Inhibiteur de pim-1 pour le traitement de néoplasmes myéloprolifératifs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2398478A1 (fr) 2000-01-26 2001-08-02 Kunio Atsumi Nouveaux derives de carbapenem de type sel quaternaire
AU2001231143A1 (en) * 2000-01-27 2001-08-07 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
US8618085B2 (en) 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
KR100557093B1 (ko) 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
AU2004297235A1 (en) 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20060004197A1 (en) 2004-07-02 2006-01-05 Thomas Thrash Sulfonamide-based compounds as protein tyrosine kinase inhibitors
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
EP1910385B1 (fr) 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazols et thiazolopyridines en tant que modulateurs de sirtuine
US8053454B2 (en) 2005-10-06 2011-11-08 Exelixis, Inc. Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
HRPK20050957B3 (en) * 2005-11-11 2008-09-30 Džanko Nikša Collapsible hanger
AR063531A1 (es) * 2006-10-31 2009-01-28 Schering Corp Derivados de anilinopiperazina y composicion farmaceutica
CA2668210C (fr) * 2006-10-31 2013-03-12 Schering Corporation Derives d'anilinopiperazine et leurs methodes d'utilisation
MX2009009304A (es) * 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
JP5241834B2 (ja) * 2007-07-19 2013-07-17 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての複素環アミド化合物
EP2195286A2 (fr) 2007-09-10 2010-06-16 Cipla Limited Procédé de préparation d'un inhibiteur de la kinase raf et intermédiaires utilisables dans ledit procédé
AR070531A1 (es) * 2008-03-03 2010-04-14 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
MX2011002365A (es) 2008-09-02 2011-04-04 Novartis Ag Derivados de picolinamida como inhibidres de cinasa.
WO2011016234A1 (fr) 2009-08-04 2011-02-10 Raqualia Pharma Inc. Dérivés de picolinamide bloqueurs de ttx-s
US8859546B2 (en) 2011-01-21 2014-10-14 Abbvie Inc. Picolinamide inhibitors of kinases

Also Published As

Publication number Publication date
TW201028393A (en) 2010-08-01
PL2344474T3 (pl) 2016-03-31
EP2344474B1 (fr) 2015-09-23
TWI434843B (zh) 2014-04-21
CO6351725A2 (es) 2011-12-20
US8329732B2 (en) 2012-12-11
JP5412519B2 (ja) 2014-02-12
US20150315150A1 (en) 2015-11-05
JP5813701B2 (ja) 2015-11-17
CA2734415A1 (fr) 2010-03-11
US20140079693A1 (en) 2014-03-20
SV2011003849A (es) 2011-07-07
BRPI0918268A2 (pt) 2020-11-17
ES2551900T3 (es) 2015-11-24
MY150136A (en) 2013-11-29
CN104311480A (zh) 2015-01-28
US8592455B2 (en) 2013-11-26
KR20110048585A (ko) 2011-05-11
ZA201101118B (en) 2011-09-28
US20100056576A1 (en) 2010-03-04
EA201100425A1 (ru) 2011-10-31
CL2011000454A1 (es) 2011-09-30
AU2009289319B2 (en) 2011-10-27
ME01291A (fr) 2013-06-20
PT2344474E (pt) 2015-12-28
AU2009289319C1 (en) 2013-12-05
IL211291A0 (en) 2011-04-28
US20120134987A1 (en) 2012-05-31
GEP20135849B (en) 2013-06-10
HK1156627A1 (en) 2012-06-15
NZ591449A (en) 2012-12-21
JP2013231049A (ja) 2013-11-14
MX2011002365A (es) 2011-04-04
CR20110114A (es) 2011-05-10
US9079889B2 (en) 2015-07-14
KR101345920B1 (ko) 2014-02-06
HN2011000629A (es) 2015-08-10
RS54506B1 (sr) 2016-06-30
NI201100052A (es) 2011-09-03
HRP20151410T1 (hr) 2016-01-15
CA2734415C (fr) 2016-07-26
HUE026381T2 (en) 2016-06-28
DOP2011000067A (es) 2017-01-15
CN102203079A (zh) 2011-09-28
SMT201600005B (it) 2016-02-25
WO2010026124A1 (fr) 2010-03-11
JP2012501314A (ja) 2012-01-19
BRPI0918268B1 (pt) 2021-08-03
CN102203079B (zh) 2014-12-10
CN103333157A (zh) 2013-10-02
HK1162022A1 (en) 2012-08-17
ECSP11010859A (es) 2011-04-29
EA020136B1 (ru) 2014-08-29
EP2344474A1 (fr) 2011-07-20
AU2009289319A1 (en) 2010-03-11
PE20110298A1 (es) 2011-05-21
UY32085A (es) 2010-03-26
SI2344474T1 (sl) 2015-12-31
IL211291A (en) 2014-05-28
DK2344474T3 (en) 2015-12-14

Similar Documents

Publication Publication Date Title
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
MA29915B1 (fr) Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases
MA32232B1 (fr) Nouveaux compoés hétérocycliques et leurs utilisations
EA201100426A1 (ru) Бициклические ингибиторы киназы
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA30607B1 (fr) N-phenylmethyl -5-oxo-proline-2-amides substitues tenant lieu d'antagonistes du recepteur p2x7 et procedes d'utilisation
BRPI0515532A (pt) composto, composição farmacêutica, métodos de inibir a ligação de ligandos endógenos ao receptor de crth-2 em uma célula, de tratar, melhorar ou prevenir um distúrbio responsivo à inibição da ligação de ligandos endógenos ao receptor de crt-2 e de preparar um composto, e, kit
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA35459B1 (fr) Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
ATE516803T1 (de) Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
MA30358B1 (fr) Quinazolines pour l'inhibition de pdk1
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
DE602007008434D1 (de) Rezeptoren
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA31016B1 (fr) Composes de diazepan substitues comme antagonistes des recepteurs de l'orexine.
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
EP1606286A4 (fr) Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA27565A1 (fr) Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
MA30988B1 (fr) Composes destines a inhiber la progression mitotique